Avenue Therapeutics appoints Alexandra MacLean, M.D. as CEO

AVENUE THERAPEUTICS, INC.

Alexandra MacLean, M.D., appointed CEO effective August 1, 2022.
Dr. MacLean previously an Entrepreneur in Residence at Fortress Biotech (FBIO).
She will receive an annual cash salary of $332,200; no employment agreement yet.
David Jin ends interim CEO role, remains interim CFO and COO.
No family relationships or transactions requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

David Jin

Interim Chief Executive Officer

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2022-08-01
Successor: Alexandra MacLean, M.D.
Filed: August 3, 2022, 7:59 PM ET

With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.

Appointed

Alexandra MacLean, M.D.

Chief Executive Officer

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2022-08-01
Filed: August 3, 2022, 7:59 PM ET

On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the “ Company ”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive Officer, with immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Jin changed role as Interim Chief Executive Officer at AVENUE THERAPEUTICS, INC..

Action: ended his term as
Role: Interim Chief Executive Officer

Exact text from the filing

With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexandra MacLean, M.D. was appointed as Chief Executive Officer at AVENUE THERAPEUTICS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the “ Company ”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive Officer, with immediate effect.

View on SEC.gov

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-085661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.